All In Biotech

Drug Trial Radar · NCT07011706

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ATI-045 in Patients With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

110

Actual

Start

May 30, 2025

Primary completion

Sep 21, 2026

Study completion Nov 24, 2026

Sponsor

Lead sponsor
Aclaris Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jun 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates ATI-045 versus placebo in patients with Moderate-to-Severe Atopic Dermatitis.

Conditions

  • Atopic Dermatitis
  • Atopic
  • Dermatitis
  • AD
  • Eczema

Interventions

  • ATI-045Drug

    ATI-045 group

  • PlaceboDrug

    Placebo group

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent Change in Eczema Area and Severity Index (EASI)Time frame: Baseline to Week 24

Locations

60 sites in 2 countries. Site status is shown where the registry gives one.

  • Aclaris Clinical Site

    Phoenix, Arizona

  • Aclaris Clinical Site

    Tucson, Arizona

  • Aclaris Study Site

    Bryant, Arkansas

  • Aclaris Clinical Site

    Beverly Hills, California

  • Aclaris Study Site

    Encinitas, California

  • Aclaris Clinical Site

    Encino, California

  • Aclaris Clinical Site

    Huntington Beach, California

  • Aclaris Study Site

    Los Angeles, California

  • Aclaris Study Site

    Oceanside, California

  • Aclaris Study Site

    Santa Monica, California

  • Aclaris Clinical Site

    Sherman Oaks, California

  • Aclaris Clinical Site

    Thousand Oaks, California

  • Aclaris Study Site

    Coral Gables, Florida

  • Aclaris Clinical Site

    Hollywood, Florida

  • Aclaris Clinical Site

    Jacksonville, Florida

  • Aclaris Clinical Site

    Margate, Florida

  • Aclaris Study Site

    North Miami Beach, Florida

  • Aclaris Study Site

    Sweetwater, Florida

  • Aclaris Study Site

    Tampa, Florida

  • Aclaris Clinical Site

    Wellington, Florida

  • Aclaris Clinical Site

    Atlanta, Georgia

  • Aclaris Clinical Site

    Savannah, Georgia

  • Aclaris Study Site

    Boise, Idaho

  • Aclaris Study Site

    Clarksville, Indiana

  • Aclaris Study Site

    Indianapolis, Indiana

  • Aclaris Clinical Site

    Lafayette, Indiana

  • Aclaris Study Site

    West Lafayette, Indiana

  • Aclaris Study Site

    Bowling Green, Kentucky

  • Aclaris Clinical Site

    Ann Arbor, Michigan

  • Aclaris Study Site

    Auburn Hills, Michigan

  • Aclaris Clinical Site

    Troy, Michigan

  • Aclaris Clinical Site

    Ridgeland, Mississippi

  • Aclaris Study Site

    Saint Joseph, Missouri

  • Aclaris Clinical Site

    Missoula, Montana

  • Aclaris Study Site

    New York, New York

  • Aclaris Study Site

    New York, New York

  • Aclaris Clinical Site

    New York, New York

  • Aclaris Clinical Site

    The Bronx, New York

  • Aclaris Clinical Site

    Cary, North Carolina

  • Aclaris Clinical Site

    Wilmington, North Carolina

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.